Evandro de Azambuja
- Oncology top 0.05%
- HER2/EGFR in Cancer Research 168
- Cancer Treatment and Pharmacology 98
- Peptidase Inhibition and Analysis 29
- Cancer Risks and Factors 25
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies 120
-
- Monoclonal and Polyclonal Antibodies Research 43
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 80
- Genetics top 1%
-
- Chemotherapy-induced cardiotoxicity and mitigation 25
Evandro de Azambuja
329 papers receiving 15.2k citations
Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 10.7k
- Cancer Research 4.7k
- Radiology, Nuclear Medicine and Imaging 2.5k
- Pulmonary and Respiratory Medicine 3.6k
- Genetics 781
Countries citing papers authored by Evandro de Azambuja
This map shows the geographic impact of Evandro de Azambuja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evandro de Azambuja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evandro de Azambuja more than expected).
Fields of papers citing papers by Evandro de Azambuja
This network shows the impact of papers produced by Evandro de Azambuja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evandro de Azambuja. The network helps show where Evandro de Azambuja may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Evandro de Azambuja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 3 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 24 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 17 | |
| 9 | 2022 | 9 | |
| 10 | 2021 | 44 | |
| 11 | 2021 | 6 | |
| 12 | 2020 | 206 | |
| 13 | 2020 | 22 | |
| 14 | 2016 | 16 | |
| 15 | 2016 | 84 | |
| 16 | 2014 | 292 | |
| 17 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98breakdown → | 2013 | 1213 |
| 18 | The landscape of medical oncology in Europe by 2020 | 2013 | 1 |
| 19 | 2008 | 11 | |
| 20 | 2005 | 5 |
About Evandro de Azambuja
Evandro de Azambuja is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 351 papers that have together received 15.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (168 papers), Breast Cancer Treatment Studies (120 papers), Cancer Treatment and Pharmacology (98 papers), Advanced Breast Cancer Therapies (80 papers), Monoclonal and Polyclonal Antibodies Research (43 papers), Peptidase Inhibition and Analysis (29 papers), Cancer Risks and Factors (25 papers) and Chemotherapy-induced cardiotoxicity and mitigation (25 papers). The work is most often cited by research in Oncology (10.7k citations), Cancer Research (4.7k citations) and Radiology, Nuclear Medicine and Imaging (2.5k citations). Evandro de Azambuja has collaborated with scholars based in Belgium, Italy and United States. Frequent co-authors include Martine Piccart, Christos Sotiriou, Matteo Lambertini, Giuseppe Viale, Sherene Loi, Gilberto de Castro, Fátima Cardoso, Hatem A. Azim, Marianne Paesmans and Richard D. Gelber. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, ESMO Open, Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.